Cemdisiran vs Eculizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Myasthenia Gravis
Shared mechanism: Complement C5 · full Myasthenia Gravis pipeline
Cemdisiran
Marketed by Alnylam Pharmaceuticals and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Eculizumab · Soliris
Marketed by AstraZeneca
NCT01997229 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 125 patients with a clinical primary endpoint, the MG-ADL daily-living score. The primary comparison was not statistically significant (difference in mean rank -11.7, 95% CI -24.33 to 0.96, p=0.0698), so the trial does not provide strong evidence of benefit despite its sound design.
Reported efficacy
Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA) (End of study (Week 26)): Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA) (End of study (Week 26)): Eculizumab 56.6 scores on a scale (Standard Error 4.53) | Placebo 68.3 scores on a scale (Standard Error 4.49) (missed)
Result source: NCT01997229
Results for Myasthenia Gravis
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Cemdisiran: no structured comparison results are available for Myasthenia Gravis.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Generalized Myasthenia Gravis
Shared mechanism: Complement C5 · full Generalized Myasthenia Gravis pipeline
Cemdisiran
Marketed by Alnylam Pharmaceuticals and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Eculizumab · Soliris
Marketed by AstraZeneca
NCT01997229 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 125 patients with a clinical primary endpoint, the MG-ADL daily-living score. The primary comparison was not statistically significant (difference in mean rank -11.7, 95% CI -24.33 to 0.96, p=0.0698), so the trial does not provide strong evidence of benefit despite its sound design.
Reported efficacy
Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA) (End of study (Week 26)): Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA) (End of study (Week 26)): Eculizumab 56.6 scores on a scale (Standard Error 4.53) | Placebo 68.3 scores on a scale (Standard Error 4.49) (missed)
Result source: NCT01997229
Results for Generalized Myasthenia Gravis
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Cemdisiran: no structured comparison results are available for Generalized Myasthenia Gravis.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cemdisiran's landscape · Eculizumab's landscape